KRAS and neoplasm: Quantitative analysis of tumor-specific mutations in ctDNA, such as single nucleotide variants in KRAS, NRAS, PIK3CA, BRAF, and EGFR, demonstrated over 80 % concordance with tumor tissue in patients with colorectal, lung, and breast cancers [9].